The manufacturer identified for Tagrix 80 mg is BEACON Pharmaceuticals Limited, Bangladesh. Beacon’s own prescribing information identifies the company as the manufacturer and gives Mymensingh, Bangladesh as the manufacturing location.
Manufacturer-product relationship
| Role | Entity |
|---|---|
| Specific product | Tagrix 80 mg |
| Active ingredient | Osimertinib |
| Specific manufacturer | BEACON Pharmaceuticals Limited |
| Country associated with manufacturer | Bangladesh |
| Reference product | TAGRISSO |
| Reference-product company | AstraZeneca |
| Original developer of osimertinib | AstraZeneca |
| Product-specific distributor | [Information requires verification] |
| Product-specific marketing authorization holder | [Information requires verification] |
Beacon Pharmaceuticals
Beacon describes itself as an oncology-focused pharmaceutical company involved in pharmaceutical development, manufacturing and international exports.
The company states that it was established in 2006 and became a public limited company in 2010.
Manufacturing and quality
Beacon publishes information about its quality-management systems, manufacturing operations and GMP-related processes.
These general company statements should not be interpreted as independent certification of every individual Tagrix batch or every country-specific authorization.
Beacon versus AstraZeneca
It is important to distinguish different pharmaceutical roles:
AstraZeneca: developer and company associated with TAGRISSO, the reference product.
Beacon Pharmaceuticals: manufacturer of Tagrix.
Tagrix should therefore not be described as an AstraZeneca product merely because both contain osimertinib. The EMA’s historical assessment documentation identifies AstraZeneca AB as the applicant for TAGRISSO‘s original European marketing-authorisation application.
Official manufacturer information
Beacon publishes corporate, quality and product information through its official resources.